Results 121 to 130 of about 5,988 (201)

Net clinical benefit of a reduced dose of DOACs in non-valvular atrial fibrillation: A meta-analysis of randomized trials

, 2022
Background: In standard dosing, direct Oral Anticoagulants (DOACs) are used as an alternative to warfarin to prevent ischemic stroke and systemic embolism in non-valvular Atrial Fibrillation (AF).
Konstantinidis, D., Tsivgoulis, G., Tsioufis, C., Thomopoulos, C., Polyzos, D., Palaiodimou, L., Ntalakouras, J.   +6 more
core  

Direct Oral Anticoagulants vs. Vitamin K Antagonists for Atrial Fibrillation in Cardiac Amyloidosis: A Systematic Review and Meta-analysis

Reviews in Cardiovascular Medicine
Background: This study aimed to systematically review and synthesize evidence comparing direct oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) for anticoagulation in patients with atrial fibrillation (AF) and cardiac ...
Qinling Nong, Shucheng Liang, Wengen Zhu, Yili Chen, Tang Zhang   +4 more
doaj   +1 more source

2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines (Part I) on Epidemiology, Detection/Screening and Integrated Patient Care in Atrial Fibrillation

Journal of Arrhythmia, Volume 42, Issue 5, October 2026.
ABSTRACT The 2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines represent the first comprehensive APHRS guidelines dedicated to the management of atrial fibrillation (AF) and comprise four parts covering epidemiology, detection/screening and integrated care; stroke prevention; rate and rhythm control; and lifestyle risk factor and comorbidity ...
Boyoung Joung, Rungroj Krittayaphong, Yutao Guo, Pil‐Sung Yang, Yu‐Cheng Hsieh, Takanori Ikeda, Daehoon Kim, Pipin Kojodjojo, Ngai‐Yin Chan, Yoga Yuniadi, Kieu Ngoc Dung, Sirin Apiyasawat, Wael Almahmeed, Eue‐Keun Choi, Melissa E. Middeldorp, Kyoko Soejima, Gregory Y. H. Lip, Hui‐Nam Pak, Tze‐Fan Chao   +18 more
wiley   +1 more source

Temporal Trends in Patient Characteristics, Anticoagulation Treatment Quality, and Clinical Outcomes of Individuals Receiving Vitamin K Antagonists in the Netherlands (2014 Until–2022)

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 10, October 2026.
ABSTRACT Objectives To describe temporal trends in the clinical landscape of vitamin K antagonist (VKA) treatment in the Netherlands, after the introduction of a lower international normalized ratio (INR) target range in 2016 and direct oral anticoagulants.
Gilda D. Zielinski, Qingui Chen, Marieke J. H. A. Kruip, Frederikus A. Klok, Suzanne C. Cannegieter, Nienke van Rein   +5 more
wiley   +1 more source

Quality of clinical Direct Oral Anticoagulants (DOACs) prescribing and identification of risk factors for inappropriate prescriptions

, 2020
AIMS: Even though the use of Direct Oral Anticoagulants (DOACs) is safe based on clinical outcomes, drug safety also depends on appropriateness of drug prescription, which is challenging for DOACs since many patient factors need to be considered. The aim
Harmsze, Ankie Maxelante, Zhang, Zhu Xian, van den Broek, Marcel Pieter Henricus, Söhne, Maaike, van de Garde, Ewoudt Meine Walraven, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics   +7 more
core  

Prescribing patterns and clinician preferences for direct oral anticoagulant use in unusual site venous thromboembolism: a cross-sectional analysis from the Direct oral anticoagulants in Unusual Site venous Thromboembolism (DUST) study

Research and Practice in Thrombosis and Haemostasis
Background: Unusual site venous thromboembolism (USVTE) presents therapeutic challenges. Direct oral anticoagulants (DOACs) are increasingly prescribed despite limited evidence from clinical trials.
Nicoletta Riva, Laurent Bertoletti, Antonio Chistolini, Valerio De Stefano, Sofia Barbar, Marco Paolo Donadini, Maria Teresa Sartori, Francis Couturaud, Michelangelo Sartori, Alexander Gatt, Omri Cohen, Chiara Fantoni, Scott Kaatz, Alenka Mavri, Isabelle Mahé, Judith Catella, Pedro Ruiz-Artacho, Giorgio Ghigliotti, Luis Jara-Palomares, Gian Marco Podda, Alessandro Squizzato, Ponlapat Rojnuckarin, Jenneke Leentjens, Marie Antoinette Sevestre, Walter Ageno   +24 more
doaj   +1 more source

Effects of DOACs on Mouse Melanoma Metastasis and the Inhibitory Mechanism of Edoxaban, a Factor Xa-Specific DOAC

TH Open
AbstractDirect oral anticoagulants (DOACs) have been widely used in patients with thromboembolism. We previously reported that among DOACs, edoxaban (EDX), a factor Xa (FXa)-specific DOAC, most effectively inhibited the growth of syngeneic non-metastatic murine colon cancer cells implanted in mice via the protease-activated receptor 2 (PAR2) pathway ...
Hiramoto, Keiichi, Watanabe, Taisei, Imai, Masashi, Suzuki, Koji   +3 more
openaire   +2 more sources

Antithrombotic Therapy Use in Children With Pulmonary Hypertension

Pulmonary Circulation, Volume 16, Issue 4, October 2026.
ABSTRACT The role of antithrombotic therapy in pulmonary hypertension (PH) remains uncertain, with conflicting adult data and limited pediatric evidence. This study aimed to describe real‐world antithrombotic use in pediatric PH utilizing Pediatric Pulmonary Hypertension Network (PPHNet) registry data and a survey of PPHNet centers. We analyzed data of
Meredith J. O'Neil, Lynn A. Sleeper, Nidhy P. Varghese, Paul J. Critser, Eric D. Austin, Catherine M. Avitabile, Angela Bates, Erika B. Rosenzweig, Carly E. Byrd, Patrick D. Evers, Stephanie S. Handler, Rachel K. Hopper, Emma O. Jackson, Roberta L. Keller, Usha S. Krishnan, Minmin Lu, Jessica Maclean, Raysa Morales‐Demori, Mary P. Mullen, Meredith Riker, Rachel T. Sullivan, Delphine Yung, Benjamin S. Frank, the Pediatric Pulmonary Hypertension Network   +23 more
wiley   +1 more source

Right Ventricular–Pulmonary Arterial Coupling by Serial TAPSE/sPAP: A Noninvasive Predictor for Clinical Outcomes in Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Circulation, Volume 16, Issue 4, October 2026.
ABSTRACT The ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure (TAPSE/sPAP) is a noninvasive surrogate of right ventricular–pulmonary arterial coupling, but its value for dynamic risk stratification in chronic thromboembolic pulmonary hypertension (CTEPH) remains uncertain.
Jing Wen, Ruzetuoheti Yiminniyaze, Yishan Li, Sugang Gong, Ling Zhu, Yuanhua Yang, Cheng Hong, Zhenwen Yang, Jun Wan, Xiaopei Cui, Hong Chen, Yingqun Ji, Chenghong Li, Zhaozhong Cheng, Yunhui Zhang, Changming Xiong, Lan Wang, Qiushang Ji, Fajiu Li, Zhu Zhang, Yunxia Zhang, Qiang Huang, Yanan Zhen, Min Liu, Lei Li, Yanan Zhai, Aili Li, Liping Fu, Shuai Zhang, Wanmu Xie, Zhenguo Zhai, Chen Wang   +31 more
wiley   +1 more source

An App‐Based Proton Pump Inhibitor Discontinuation Tool: A Multicentre, Open‐Label, Randomised Superiority Trial

United European Gastroenterology Journal, Volume 14, Issue 8, October 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) are frequently used without long‐term indication. Discontinuation remains challenging because of rebound symptoms. Whether digital guidance tools improve discontinuation is unknown. We evaluated whether an app improves PPI discontinuation.
Lieke M. Koggel, Thomas Timmers, Marten A. Lantinga, Rudolf B. Kool, Cornelis Kramers, Noortje van Herwaarden, Peter D. Siersema, on behalf of the SUPPORT study consortium, B. A. J. Veldman, A. C. I. T. L. Tan, L. B. Hilbrands, I. L. Meek   +11 more
wiley   +1 more source